Screening for skin cancer: Who is at risk?

by Mayo Clinic News NetworkCredit: Unsplash/CC0 Public DomainThere are three major kinds of skin cancer—squamous cell carcinoma, basal cell carcinoma and melanoma. Melanoma is the most dangerous. The

Updated on: September 07,2024 0

Screening for skin cancer: Who is at risk?

by Mayo Clinic News NetworkCredit: Unsplash/CC0 Public DomainThere are three major kinds of skin cancer—squamous cell carcinoma, basal cell carcinoma and melanoma. Melanoma is the most dangerous. The

Updated on:September 07,2024 0

FDA approves Leqselvi for severe alopecia

by Lori SolomonThe U.S. Food and Drug Administration has approved Leqselvi (deuruxolitinib) tablets for the treatment of adults with severe alopecia areata.Leqselvi (8 mg) is a twice-daily oral select

Updated on: August 30,2024 0

FDA approves Leqselvi for severe alopecia

by Lori SolomonThe U.S. Food and Drug Administration has approved Leqselvi (deuruxolitinib) tablets for the treatment of adults with severe alopecia areata.Leqselvi (8 mg) is a twice-daily oral select

Updated on:August 30,2024 0

Sweden sees skin cancer decline in under-50s for 1st time: Study

Credit: Anna Tarazevich from PexelsSkin cancer is declining among younger adults in Sweden for the first time after decades of increases, making it the first European country to see a fall, researcher

Updated on: September 27,2024 0

Sweden sees skin cancer decline in under-50s for 1st time: Study

Credit: Anna Tarazevich from PexelsSkin cancer is declining among younger adults in Sweden for the first time after decades of increases, making it the first European country to see a fall, researcher

Updated on:September 27,2024 0

The dirty business of beauty | DW Documentary

Updated on: September 05,2024 0

The dirty business of beauty | DW Documentary

Updated on:September 05,2024 0

Vitiligo: Loss of skin's pigment-producing cells could be related to basement membrane disruption

byOsaka Metropolitan UniversityA graphical representation illustrates what might be occurring in undamaged and damaged skin. Credit: Osaka Metropolitan UniversitySkin pigmentation disorders affe

Updated on: September 25,2024 0

Vitiligo: Loss of skin's pigment-producing cells could be related to basement membrane disruption

byOsaka Metropolitan UniversityA graphical representation illustrates what might be occurring in undamaged and damaged skin. Credit: Osaka Metropolitan UniversitySkin pigmentation disorders affe

Updated on:September 25,2024 0

Sex matters in how, when, and where melanomas develop

byElsevierFitted temporal trend of invasive cutaneous melanoma incidence (1982- 2018) for males vs. females from three populations (Queensland, US Whites, Scotland), by body site. Credit:J

Updated on: September 27,2024 0

Sex matters in how, when, and where melanomas develop

byElsevierFitted temporal trend of invasive cutaneous melanoma incidence (1982- 2018) for males vs. females from three populations (Queensland, US Whites, Scotland), by body site. Credit:J

Updated on:September 27,2024 0

Study finds link between eczema and peripheral vascular disease

byYale School of MedicineCredit: Unsplash/CC0 Public DomainPeople living with atopic dermatitis (AD, also known as eczema) are also at significantly higher risk for peripheral vascular disease (

Updated on: November 06,2024 0

Study finds link between eczema and peripheral vascular disease

byYale School of MedicineCredit: Unsplash/CC0 Public DomainPeople living with atopic dermatitis (AD, also known as eczema) are also at significantly higher risk for peripheral vascular disease (

Updated on:November 06,2024 0

Long-term upadacitinib use feasible for adolescents with atopic dermatitis

by Lori SolomonLong-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23

Updated on: November 13,2024 0

Long-term upadacitinib use feasible for adolescents with atopic dermatitis

by Lori SolomonLong-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23

Updated on:November 13,2024 0